CRISPR/Cas9 screening platform have been used to identify genetic vulnerabilities in acute myeloid leukemia (AML) cells, including several established (such as DOT1L, BCL2, and MEN1) and novel (such as KAT2A) therapeutic targets for AML [88]. This evidence concerns the gene DOT1L and acute myeloid leukemia.